Multivalent interactions: Old concept, new tricks Dr Stefano Angioletti Uberti, Senior Lecturer at Imperial College London Arguably,multivalency has been used since the 1970s as a mechanism to increase the binding … Read more
Ref: RT-SS //Deadline: 25/02/2025
The Institute of Bioengineering of Catalunya (IBEC) reaffirms its commitment to scientific education by renewing for the fifth consecutive time its accreditation as a Unit of Scientific Culture and Innovation … Read more
Green Disc: open-access community-driven Digital Sustainability Certification scheme Loïc Lannelongue, Research Associate at University of Cambridge From genetic studies and astrophysics simulations to AI, scientific computing has enabled amazing discoveries … Read more
Científicos del IBEC, liderados por Xavier Trepat, han desarrollado MIRO, un dispositivo que recrea el entorno tumoral para estudiar su respuesta a tratamientos. Publicado en Nature Communications, permite analizar por … Read more
On the occasion of World Cancer Day, celebrated on 4 February, more than 50 nanomedicine experts gathered today at the ‘Nano World Cancer Day’ event, held at the Vall d’Hebron … Read more
Investigadores de l’Hospital del Mar y del IBEC están desarrollando un dispositivo para mejorar los resultados de los tratamientos de inmunoterapia contra el cáncer. Este dispositivo podría optimizar la eficacia … Read more
Investigadores del IBEC y del Hospital del Mar han desarrollado MIRO, un dispositivo que recrea fielmente el entorno tumoral con células de pacientes. Esta innovadora tecnología permite estudiar la interacción … Read more
The Micro Immune Response On chip (MIRO) allows tumours and their environment to be replicated in order to understand their response to treatment. The device, which has already been successfully tested on breast cancer samples, could be key to developing new treatments and determining the most appropriate therapy for each patient in a personalized way. The work, published in Nature Communications, is the result of a collaboration between the Institute for Bioengineering of Catalonia and the Research Institute of the Hospital del Mar.
